Literature DB >> 17948931

Innate immunity in inflammatory bowel disease.

Jesus-K Yamamoto-Furusho1, Daniel-K Podolsky.   

Abstract

The human intestinal tract is home to an enormous bacterial flora. The host defense against microorganisms can be divided into innate and adaptive immunity. The former is the most immediate line of response to immunologic challenges presented by bacteria, viruses, and fungi. The mucosal immune system has evolved to balance the need to respond to pathogens while co-existing with commensal bacteria and food antigens. In inflammatory bowel disease (IBD), this hyporesponsiveness or tolerance breaks down and inflammation supervenes driven by the intestinal microbial flora. Bacteria contain compounds and are recognized by a variety of receptors, including Toll-like receptors (TLRs) and NODs (a family of intracellular bacterial sensors) and are potent stimuli of innate immune responses. Several mutations in these receptors have been associated with development of IBD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17948931      PMCID: PMC4172736          DOI: 10.3748/wjg.v13.i42.5577

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  37 in total

Review 1.  Inflammatory bowel disease.

Authors:  Daniel K Podolsky
Journal:  N Engl J Med       Date:  2002-08-08       Impact factor: 91.245

2.  Cytoplasmic flagellin activates caspase-1 and secretion of interleukin 1beta via Ipaf.

Authors:  Edward A Miao; Celia M Alpuche-Aranda; Monica Dors; April E Clark; Martin W Bader; Samuel I Miller; Alan Aderem
Journal:  Nat Immunol       Date:  2006-04-30       Impact factor: 25.606

3.  Cytosolic flagellin requires Ipaf for activation of caspase-1 and interleukin 1beta in salmonella-infected macrophages.

Authors:  Luigi Franchi; Amal Amer; Mathilde Body-Malapel; Thirumala-Devi Kanneganti; Nesrin Ozören; Rajesh Jagirdar; Naohiro Inohara; Peter Vandenabeele; John Bertin; Anthony Coyle; Ethan P Grant; Gabriel Núñez
Journal:  Nat Immunol       Date:  2006-04-30       Impact factor: 25.606

4.  An open-labelled study of granulocyte colony-stimulating factor in the treatment of active Crohn's disease.

Authors:  J R Korzenik; B K Dieckgraefe
Journal:  Aliment Pharmacol Ther       Date:  2005-02-15       Impact factor: 8.171

5.  Nucleotide-binding oligomerization domain-2 modulates specific TLR pathways for the induction of cytokine release.

Authors:  Mihai G Netea; Gerben Ferwerda; Dirk J de Jong; Trees Jansen; Liesbeth Jacobs; Matthijs Kramer; Ton H J Naber; Joost P H Drenth; Stephen E Girardin; Bart Jan Kullberg; Gosse J Adema; Jos W M Van der Meer
Journal:  J Immunol       Date:  2005-05-15       Impact factor: 5.422

6.  NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression.

Authors:  J Wehkamp; J Harder; M Weichenthal; M Schwab; E Schäffeler; M Schlee; K R Herrlinger; A Stallmach; F Noack; P Fritz; J M Schröder; C L Bevins; K Fellermann; E F Stange
Journal:  Gut       Date:  2004-11       Impact factor: 23.059

7.  NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses.

Authors:  Tomohiro Watanabe; Atsushi Kitani; Peter J Murray; Warren Strober
Journal:  Nat Immunol       Date:  2004-06-27       Impact factor: 25.606

8.  Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease.

Authors:  Naohiro Inohara; Yasunori Ogura; Ana Fontalba; Olga Gutierrez; Fernando Pons; Javier Crespo; Koichi Fukase; Seiichi Inamura; Shoichi Kusumoto; Masahito Hashimoto; Simon J Foster; Anthony P Moran; Jose L Fernandez-Luna; Gabriel Nuñez
Journal:  J Biol Chem       Date:  2003-01-04       Impact factor: 5.157

9.  Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection.

Authors:  Stephen E Girardin; Ivo G Boneca; Jérôme Viala; Mathias Chamaillard; Agnès Labigne; Gilles Thomas; Dana J Philpott; Philippe J Sansonetti
Journal:  J Biol Chem       Date:  2003-01-13       Impact factor: 5.157

10.  NOD2 mediates anti-inflammatory signals induced by TLR2 ligands: implications for Crohn's disease.

Authors:  Mihai G Netea; Bart Jan Kullberg; Dirk J de Jong; Barbara Franke; Tom Sprong; Ton H J Naber; Joost P H Drenth; Jos W M Van der Meer
Journal:  Eur J Immunol       Date:  2004-07       Impact factor: 5.532

View more
  27 in total

1.  MyD88 signaling in nonhematopoietic cells protects mice against induced colitis by regulating specific EGF receptor ligands.

Authors:  Katharina Brandl; Lei Sun; Christina Neppl; Owen M Siggs; Sylvain M Le Gall; Wataru Tomisato; Xiaohong Li; Xin Du; Daniela N Maennel; Carl P Blobel; Bruce Beutler
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-01       Impact factor: 11.205

Review 2.  Applying nanomedicine in maladaptive inflammation and angiogenesis.

Authors:  Amr Alaarg; Carlos Pérez-Medina; Josbert M Metselaar; Matthias Nahrendorf; Zahi A Fayad; Gert Storm; Willem J M Mulder
Journal:  Adv Drug Deliv Rev       Date:  2017-05-12       Impact factor: 15.470

Review 3.  Role of the gut microbiota in inflammatory bowel disease pathogenesis: what have we learnt in the past 10 years?

Authors:  Georgina L Hold; Megan Smith; Charlie Grange; Euan Robert Watt; Emad M El-Omar; Indrani Mukhopadhya
Journal:  World J Gastroenterol       Date:  2014-02-07       Impact factor: 5.742

4.  Extracellular matrix protein lumican regulates inflammation in a mouse model of colitis.

Authors:  Kristin Lohr; Hardik Sardana; Seakwoo Lee; Feng Wu; David L Huso; Abdel Rahim Hamad; Shukti Chakravarti
Journal:  Inflamm Bowel Dis       Date:  2011-04-11       Impact factor: 5.325

5.  Milk fat globule-epidermal growth factor 8 is decreased in intestinal epithelium of ulcerative colitis patients and thereby causes increased apoptosis and impaired wound healing.

Authors:  Qiu-jie Zhao; Yan-bo Yu; Xiu-li Zuo; Yan-yan Dong; Yan-qing Li
Journal:  Mol Med       Date:  2012-05-09       Impact factor: 6.354

6.  Murine norovirus: an intercurrent variable in a mouse model of bacteria-induced inflammatory bowel disease.

Authors:  Karen Chase Lencioni; Audrey Seamons; Piper M Treuting; Lillian Maggio-Price; Thea Brabb
Journal:  Comp Med       Date:  2008-12       Impact factor: 0.982

7.  Investigation of innate immunity genes CARD4, CARD8 and CARD15 as germline susceptibility factors for colorectal cancer.

Authors:  Nikolaus Möckelmann; Witigo von Schönfels; Stephan Buch; Oliver von Kampen; Bence Sipos; Jan Hendrik Egberts; Philip Rosenstiel; Andre Franke; Mario Brosch; Sebastian Hinz; Christian Röder; Holger Kalthoff; Ulrich R Fölsch; Michael Krawczak; Stefan Schreiber; Clemens Dieter Bröring; Jürgen Tepel; Clemens Schafmayer; Jochen Hampe
Journal:  BMC Gastroenterol       Date:  2009-10-20       Impact factor: 3.067

Review 8.  Rheumatic manifestations of inflammatory bowel disease.

Authors:  Tatiana Sofía Rodríguez-Reyna; Cynthia Martínez-Reyes; Jesús Kazúo Yamamoto-Furusho
Journal:  World J Gastroenterol       Date:  2009-11-28       Impact factor: 5.742

9.  Implication of intestinal VDR deficiency in inflammatory bowel disease.

Authors:  Jung-Hwan Kim; Satoshi Yamaori; Tomotaka Tanabe; Caroline H Johnson; Kristopher W Krausz; Shigeaki Kato; Frank J Gonzalez
Journal:  Biochim Biophys Acta       Date:  2012-10-02

10.  Ubiquitin-editing enzyme A20 promotes tolerance to lipopolysaccharide in enterocytes.

Authors:  Jin Wang; Yannan Ouyang; Yigit Guner; Henri R Ford; Anatoly V Grishin
Journal:  J Immunol       Date:  2009-07-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.